Get Your Personalized Supplement StackSupplement Stack Quiz

Angelica Gigas Nakai

Q: Is Angelica gigas Nakai safe for long-term use?

Current research suggests AGN is safe for short to medium-term use, as no serious adverse events have been reported in clinical trials. However, long-term safety data are still limited, and more extensive studies are needed to confirm its safety over prolonged periods.

Q: Can it be used for cognitive decline?

Preclinical animal studies show promising results for Angelica gigas Nakai in improving cognitive function. However, human clinical trials are necessary to confirm these effects and establish its efficacy for treating cognitive decline in humans.

Q: Does it interact with medications?

Angelica gigas Nakai may potentially interact with medications, particularly blood thinners (anticoagulants) and lipid-lowering drugs, due to its effects on blood lipids and circulation. It is crucial to consult a healthcare provider before use if you are taking any prescription medications.

Q: How soon can benefits be expected?

Benefits related to lipid reduction and pain relief have been observed within weeks in clinical trials. Cognitive benefits, primarily studied in animal models, require further human research to determine their onset and duration.

Q: Is the whole root or extract better?

Extracts, especially those formulated for enhanced bioavailability (e.g., hot-melt extrusion), are generally considered more effective than crude whole root preparations. These advanced formulations improve the absorption and delivery of the active compounds.

Also known as: Korean Angelica, Dang Gui, Angelica gigas Nakai

Overview

Angelica gigas Nakai (AGN) is a traditional medicinal herb native to East Asia, particularly Korea, where its roots have been historically used in herbal medicine. It is classified as a botanical supplement and is gaining recognition in modern research for its diverse therapeutic potential. Traditionally, AGN has been employed for improving blood circulation, alleviating pain, enhancing cognitive function, and supporting vascular health. Contemporary scientific investigations are exploring its efficacy in managing conditions such as dyslipidemia, memory impairment, chronic pain, and even its potential role in cancer therapy. The herb's pharmacological effects are attributed to its rich composition of bioactive compounds, notably decursin, decursinol angelate, and decursinol. While research on AGN is still emerging, there is a growing body of clinical and preclinical studies, including some randomized controlled trials (RCTs) and pharmacokinetic analyses, supporting its traditional uses and uncovering new applications. The quality of evidence is moderate, with well-designed clinical trials providing insights into its benefits, though comprehensive systematic reviews and meta-analyses specifically on AGN are still limited.

Benefits

Angelica gigas Nakai offers several evidence-based benefits, with varying strengths of evidence: * **Blood Lipid Modulation:** Strong evidence from a randomized, double-blind, placebo-controlled clinical trial (Jung et al., 2020) demonstrated that AGN extract significantly reduced blood triglyceride levels compared to placebo (p < 0.05). This suggests a clinically relevant benefit for individuals with dyslipidemia. * **Pain Relief and Functional Recovery:** Recent clinical research (Jo et al., 2024) indicates AGN's efficacy in pain relief and chondroprotection, suggesting potential benefits for joint health and functional recovery, particularly in conditions involving pain and cartilage degradation. The effect sizes were statistically significant and clinically relevant. * **Cognitive Enhancement:** Preclinical evidence from an in vivo study (Piao et al., 2015) showed that a hot-melt extrusion formulation of AGN significantly improved cognitive function in memory-impaired mice. While promising, these findings require confirmation through human clinical trials to establish efficacy in humans. * **Anticancer Potential:** Reviews (Sestito et al., 2024) highlight the anticancer properties of AGN's bioactive compounds (decursin, decursinol angelate) observed in in vitro and in vivo studies. However, clinical evidence in humans is still preliminary and further research is needed. * **Vascular Health:** Emerging evidence suggests AGN's antioxidant activity supports its use in vascular disease treatment, potentially improving endothelial function and lipid profiles (News-Medical.net, 2023). This area requires more robust clinical trials. Benefits related to lipid modulation and pain relief have been observed in clinical trials, primarily involving East Asian populations. Cognitive benefits, while promising in animal models, need human validation. The time course for benefits in clinical trials ranged from weeks to months, with acute effects observed in animal studies.

How it works

Angelica gigas Nakai exerts its effects through multiple biological pathways. Its primary mechanism involves the modulation of lipid metabolism, leading to a reduction in triglyceride levels. The active compounds, decursin and decursinol angelate, possess significant anti-inflammatory and antioxidant properties, which contribute to its pain-relieving effects and vascular protection. These compounds interact with various signaling pathways involved in inflammation, oxidative stress, and cell proliferation. In the nervous system, AGN exhibits neuroprotective actions, potentially by enhancing the bioavailability of its active metabolites, thereby improving cognitive function. Formulations like hot-melt extrusion significantly increase the oral bioavailability of these active compounds, allowing for more effective interaction with target systems, including the cardiovascular, nervous, and musculoskeletal systems.

Side effects

Angelica gigas Nakai generally appears to be safe, with no serious adverse events reported in clinical trials to date. However, comprehensive safety data, especially from large-scale, long-term studies, are limited. * **Common Side Effects (>5%):** No significant common side effects have been well-documented or reported in controlled clinical trials. This suggests a relatively low incidence of frequent adverse reactions. * **Uncommon Side Effects (1-5%):** Data are insufficient to definitively list uncommon side effects. Continued monitoring in broader populations is recommended to identify any less frequent adverse reactions. * **Rare Side Effects (<1%):** Due to the limited availability of large-scale safety data, rare side effects are currently unknown. More extensive post-market surveillance and larger clinical trials are needed to identify any rare but potentially serious adverse events. * **Drug Interactions:** Potential interactions exist due to AGN's effects on blood lipids and circulation. Caution is advised for individuals taking anticoagulants (blood thinners) or lipid-lowering medications, as AGN could theoretically potentiate their effects. However, specific clinical data on these interactions are currently lacking. * **Contraindications:** No specific contraindications have been formally established. However, due to a lack of sufficient safety data, caution is strongly advised for pregnant and lactating women. It is recommended that these individuals avoid AGN or consult a healthcare provider before use. * **Special Population Considerations:** Data on the safety of AGN in special populations, such as the elderly or individuals with chronic medical conditions, are limited. These individuals should consult a healthcare provider before initiating AGN supplementation to assess potential risks and benefits.

Dosage

The optimal dosage for Angelica gigas Nakai is not yet fully established, but clinical trials provide some guidance. Standardized extracts are typically used, with doses ranging from **500 mg to 1 gram daily**. These dosages have been sufficient to achieve significant reductions in triglycerides and provide pain relief in clinical studies. The maximum safe dose has not been clearly defined, but no toxicity has been reported at the studied dosages. For consistent benefits, daily dosing is recommended. The timing relative to meals has not been specifically indicated as a critical factor. It's important to note that the formulation type significantly impacts absorption and bioavailability. Enhanced bioavailability formulations, such as those utilizing hot-melt extrusion (e.g., with Soluplus), have been shown to significantly increase the absorption of active metabolites (up to 8.75-fold for decursinol). Therefore, products with such advanced formulations may achieve efficacy at lower doses or provide superior results compared to crude or less optimized extracts. No specific cofactors are identified as necessary for AGN's efficacy.

FAQs

Is Angelica gigas Nakai safe for long-term use?

Current research suggests AGN is safe for short to medium-term use, as no serious adverse events have been reported in clinical trials. However, long-term safety data are still limited, and more extensive studies are needed to confirm its safety over prolonged periods.

Can it be used for cognitive decline?

Preclinical animal studies show promising results for Angelica gigas Nakai in improving cognitive function. However, human clinical trials are necessary to confirm these effects and establish its efficacy for treating cognitive decline in humans.

Does it interact with medications?

Angelica gigas Nakai may potentially interact with medications, particularly blood thinners (anticoagulants) and lipid-lowering drugs, due to its effects on blood lipids and circulation. It is crucial to consult a healthcare provider before use if you are taking any prescription medications.

How soon can benefits be expected?

Benefits related to lipid reduction and pain relief have been observed within weeks in clinical trials. Cognitive benefits, primarily studied in animal models, require further human research to determine their onset and duration.

Is the whole root or extract better?

Extracts, especially those formulated for enhanced bioavailability (e.g., hot-melt extrusion), are generally considered more effective than crude whole root preparations. These advanced formulations improve the absorption and delivery of the active compounds.

Research Sources

https://pubmed.ncbi.nlm.nih.gov/39125316/ – This clinical research by Jo et al. (2024) indicates that Angelica gigas Nakai is effective in pain relief and chondroprotection. It suggests potential benefits for joint health and functional recovery, highlighting its clinical relevance for conditions involving pain.
https://www.mdpi.com/2072-6643/12/2/377 – Jung et al. (2020) conducted a randomized, double-blind, placebo-controlled clinical trial demonstrating that Angelica gigas Nakai extract significantly reduced blood triglyceride levels. This study provides strong evidence for its potential in dyslipidemia management.
https://onlinelibrary.wiley.com/doi/10.1002/fsn3.4376 – Sestito et al. (2024) reviewed the anticancer potential of decursin and related compounds found in Angelica gigas Nakai. The review summarizes preclinical data, indicating promising in vitro and in vivo anticancer properties, though clinical evidence is still preliminary.
https://www.news-medical.net/news/20231228/Angelica-gigas-extract-emerges-as-a-potential-treatment-for-vascular-disease.aspx – This news article from News-Medical.net (2023) discusses emerging research suggesting Angelica gigas extract as a potential treatment for vascular disease. It highlights the herb's antioxidant activity and its role in improving endothelial function and lipid profiles.
https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0124447 – Piao et al. (2015) conducted a preclinical study showing that a hot-melt extrusion formulation of Angelica gigas Nakai significantly increased the bioavailability of its active compounds and improved cognitive function in memory-impaired mice. This research highlights the importance of formulation for efficacy and suggests cognitive benefits.